Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1583 | 0.4121 | 1 |
Mycobacterium ulcerans | transglutaminase family protein | 0.1583 | 0.4121 | 0.5 |
Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0227 | 0.0475 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium tuberculosis | Hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium tuberculosis | Long conserved protein | 0.1583 | 0.4121 | 0.5 |
Brugia malayi | Thioredoxin family protein | 0.1583 | 0.4121 | 1 |
Echinococcus multilocularis | Transglutaminase | 0.1583 | 0.4121 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Giardia lamblia | Transglutaminase/protease, putative | 0.1583 | 0.4121 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.0174 | 0.0333 | 1 |
Trichomonas vaginalis | peptide N-glycanase, putative | 0.1583 | 0.4121 | 0.5 |
Echinococcus granulosus | Transglutaminase | 0.1583 | 0.4121 | 0.5 |
Mycobacterium ulcerans | putative transglutaminase-like protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC50 (functional) | > 50 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 35218 after 24 hrs by MTT assay | ChEMBL. | 21856050 |
MIC50 (functional) | > 50 ug ml-1 | Antifungal activity against Escherichia coli ATCC 10231 after 48 hrs by MTT assay | ChEMBL. | 21856050 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.